In June, GSK released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial of Blenrep in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary ... difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced ...

There is also a supplementary section to the form for managers where more than one location is included in the application. You will need to use one copy of this section for each additional location.

We list the best online form builders, to make building forms simple and easy in order to collect customer feedback and marketing data. If you are looking for a simple, fast, and easy way to ...

GSK is the sponsor of the IND application and plans to develop IDE275 ... see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the ...

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start ... information on the application, visit aionlabs.com.

(2) MOUNTAIN HIGH has been costly to follow but can still win. (9) WHISTLING STRAIT is worth a market check. (3) SUNFIRE has the form and experience to make her presence felt. (11) PINK PIGEON has ...